Drug Combination Details
| General Information of the Combination (ID: C99856) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | SMC3 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SOD Mn | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H23 | CVCL_1547 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells. J Cell Biochem. 2009 Dec 1;108(5):1125-31. | |||
